

UNITED STATES PATENT AND TRADEMARK OFFICE



ON

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. FIRST NAMED INVENTOR FILING DATE APPLICATION NO. 6006-023 6863 Denes Marton 09/853,985 05/11/2001 02/07/2003 **EXAMINER** David G. Rosenbaum ROSENBAUM & ASSOCIATES, P.C. NERBUN, PETER P Suite # 3653 875 North Michigan Avenue PAPER NUMBER ART UNIT Chicago, IL 60611 3765

DATE MAILED: 02/07/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 07-01)

		Application No.	Applicant(s)
Office Action Summary		09/853,985	MARTON, DENES
		Examiner	Art Unit
		Peter P Nerbun	3765
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status			
1)⊠	Responsive to communication(s) filed on 11 /	<u>//ay 2001</u> .	
2a) 🗌	This action is FINAL . 2b)⊠ Thi	is action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims			
4)⊠	Claim(s) <u>1-20</u> is/are pending in the application		
	4a) Of the above claim(s) is/are withdraw	vn from consideration.	
5)	Claim(s) is/are allowed.		
6)⊠)⊠ Claim(s) <u>1-13 and 16-20</u> is/are rejected.		
7)⊠ Claim(s) <u>14 and 15</u> is/are objected to.			
8) Claim(s) are subject to restriction and/or election requirement. Application Papers			
9) The specification is objected to by the Examiner.			
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.			
12)☐ The oath or declaration is objected to by the Examiner.			
Priority under 35 U.S.C. §§ 119 and 120			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:			
1. Certified copies of the priority documents have been received.			
	2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).			
* See the attached detailed Office action for a list of the certified copies not received.			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).			
 a) ☐ The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121. 			
Attachment(s)			
2) Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) atent Application (PTO-152)

Application/Control Number: 09/853,985

Art Unit: 3765

In accordance with 37 CFR 1.72, the Abstract of the Disclosure must be shortened so as to be less than 150 words.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-3, 6, and 16-20 are rejected under 35 U.S.C. 102(e) as being anticipated by Sogard et al. The patent to Sogard et al discloses an implantable medical device comprising a self-supporting structural member 20, Fig. 6 fabricated of a plurality of laminated layers 14, 19 (see col. 10, lines 60-67 and col. 11, lines 1-4) of at least one biocompatible material. Note that the planar sheets 16, Fig. 3 which comprise the layers 14 may be made from a film (see col. 10, lines 2-5). The self-supporting structural member further comprises a stent 10 having a plurality of structural elements. With regard to claim 16 note that a plurality of micro-openings may pass through a wall thickness of each tubular member 14, 19 (see col. 10, lines 1-2 which define the size of these openings as 2 to 10 microns).

Claims 1-5 and 7-13 are rejected under 35 U.S.C. 102(a) as being anticipated by Lentz et al. The patent to Lentz et al discloses an implantable medical device comprising a self-supporting structural member 10, Fig. 1 fabricated of a plurality of

laminated layers 20, 22, 28 of at least one biocompatible material. The self-supporting structural member further comprises a stent 28 and a graft 25. The stents may be constructed from stainless steel (col. 5, lines 45-49).

Claims 14 and 15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter P Nerbun whose telephone number is 703-308-0955. The examiner can normally be reached on M-F (1st Week) M-Th (2d Week).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John J Calvert can be reached on 703-305-1025. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-0758 for regular communications and - for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0861.

Peter Nerbun February 6, 2003

Peter Nerbun Primary Examiner